The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Trials of interest in newly diagnosed myeloma presented at IMS 2024
Jesús San Miguel, MD, PhD, University of Navarra, Pamplona, Spain, discusses key advances in the treatment of newly diagnosed multiple myeloma (MM), outlining the most relevant trials, presented at the International Myeloma Society (IMS) Annual Meeting, exploring combination therapies for both transplant-eligible and ineligible patients. Prof. San Miguel highlights the potential of anti-CD38 monoclonal antibody-containing regimens for improving progression-free survival (PFS) and briefly speaks on a study investigating measurable residual disease (MRD)-adapted therapy. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
JSM declares participation on advisory boards and consulting services, on behalf of my Institution, for Abbvie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen-Cilag, Karyopharm, MSD, Novartis, Pfizer, Takeda, Regeneron, Roche, Sanofi, and SecuraBio.
